Opinions

Peter Hodson Omnix Biopharmaceuticals OMRI-Q PAST TOP PICK Oct 15, 2007

(A Top Pick Nov 20/06. Up 30%.) Missed a quarter and there were competitive threats so he got out and missed the upswing.

Peter Hodson

Unlock Rating

$37.820

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TOP PICK

Using plasma to stop bleeding in the surgical applications. 200% growth. Sells at about 20 X earnings. Management owns a big chunk. Just reported stellar numbers. Will ultimately get taken over.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson Omnix Biopharmaceuticals OMRI-Q PAST TOP PICK Oct 15, 2007

You might be interested:

Omnix Biopharmaceuticals(OMRI-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Stockchase Insights

Rebecca Teltscher

Andrey Omelchak

The Panic-Proof Portfolio (Stockchase Research)

The Monthly Gems by Allan Tong